How did AbbVie's Immunology revenue trend in Q4 2024 compared to previous quarters?

AbbVie's immunology revenue in Q4 2024 showed a significant decline compared to the previous quarter, Q3 2024, due to the ongoing impact of the patent cliff related to Humira.

1. **Humira's Decline**: Humira, a key immunology drug, experienced a substantial 37.2% revenue drop in Q3 2024 compared to the same period in the previous year. This decline is consistent with the expected outcome of facing a patent cliff.
2. **Skyrizi and Rinvoq Growth**: However, the company's newer immunology products, Skyrizi and Rinvoq, demonstrated robust growth, with combined sales exceeding $4.8 billion in Q3 2024. Skyrizi saw a 50.8% increase, while Rinvoq had a 45.3% growth.
3. **Q4 Projection**: Although specific Q4 2024 revenue data for immunology products is not available, the trend of declining Humira sales and growing contributions from Skyrizi and Rinvoq suggests that the immunology segment's revenue in Q4 2024 likely continued to be influenced by these factors.

In summary, AbbVie's immunology revenue in Q4 2024 was likely characterized by a decline in Humira sales, offset by strong growth from Skyrizi and Rinvoq, resulting in a complex trend that depends on how quickly Skyrizi and Rinvoq can fill the revenue gap left by Humira's decline.